<SEC-DOCUMENT>0001437749-21-015199.txt : 20210621
<SEC-HEADER>0001437749-21-015199.hdr.sgml : 20210621
<ACCEPTANCE-DATETIME>20210621092522
ACCESSION NUMBER:		0001437749-21-015199
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20210621
DATE AS OF CHANGE:		20210621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		211027768

	BUSINESS ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>dffn20210618_defa14a.htm
<DESCRIPTION>FORM DEFA14A
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 4/28/2021 4:48:38 PM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>dffn20210428_def14a.htm</title>


</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b><br>
<b>SECURITIES AND EXCHANGE COMMISSION</b><br>
<b>Washington, D.C. 20549</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SCHEDULE 14A</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Proxy Statement Pursuant to Section 14(a) of<br>
the Securities Exchange Act of 1934 (Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="2" style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Filed by the Registrant&nbsp;&nbsp;&#9746;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="2" style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Filed by a Party other than the Registrant&nbsp;&nbsp;&#9744;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="2" style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Check the appropriate box:</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9744;</p>
			</td>
			<td>
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Preliminary Proxy Statement</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9744;</p>
			</td>
			<td>
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</b></p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9744;</p>
			</td>
			<td>
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Definitive Proxy Statement</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9746;</p>
			</td>
			<td>
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Definitive Additional Materials</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9744;</p>
			</td>
			<td>
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Soliciting Material under &#167;240.14a-12</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div style="text-align: center;"><img alt="d01.jpg" src="d01.jpg"></div>

<div style="text-align: center;">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Diffusion Pharmaceuticals Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Name of Registrant as Specified In Its Charter)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Not Applicable</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td colspan="2" style="vertical-align:top;width:53.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Payment of Filing Fee (Check the appropriate box):</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9746;</p>
			</td>
			<td>
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">No fee required.</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td>
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title of each class of securities to which transaction applies:</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Aggregate number of securities to which transaction applies:</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3)</p>
			</td>
			<td style="border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(4)</p>
			</td>
			<td style="border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Proposed maximum aggregate value of transaction:</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(5)</p>
			</td>
			<td style="border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total fee paid:</p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td>
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Fee paid previously with preliminary materials.</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td>
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amount Previously Paid:</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form, Schedule or Registration Statement No.:</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3)</p>
			</td>
			<td style="border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Filing Party:</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(4)</p>
			</td>
			<td style="border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date Filed:</p>
			</td>
		</tr>

</table>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div contenteditable="false" docsect="1" id="198008" sectdesc="Section">&nbsp;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="img01.jpg" src="img01.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>Diffusion Pharmaceuticals Reminds Stockholders to </b></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>Vote Shares In Advance of Annual Meeting</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Annual Meeting Scheduled for June 25, 2021 1 p.m. EDT</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CHARLOTTESVILLE, Va., June 18, 2021 --&nbsp;<u><b>Diffusion Pharmaceuticals Inc.</b></u><b> (NASDAQ: DFFN)</b>&nbsp;(&#8220;Diffusion,&#8221; &#8220;we&#8221; or the &#8220;Company&#8221;), an innovative biopharmaceutical company developing novel therapies that enhance the body&#8217;s ability to deliver oxygen to areas where it is needed most, reminds stockholders to vote on the proposals listed in the Company&#8217;s proxy statement in advance of its upcoming annual meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stockholders of record on May 5, 2021 should have previously received proxy materials in connection with Diffusion&#8217;s 2021 Annual Meeting of Stockholders to be held Friday, June 25, 2021, at 1:00 p.m. EDT (&#8220;Annual Meeting&#8221;). As set forth in the proxy materials, the Annual Meeting will be conducted as a virtual meeting hosted via a live webcast. Stockholders will be able to listen, vote, and submit questions from any location with internet connectivity. Stockholders or their proxy holder will be able to attend the Annual Meeting online, vote, and submit questions by following the instructions provided in their Notice Regarding the Availability of Proxy Materials and proxy statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe the vote of each of our stockholders is important. Whether shares are held directly as a stockholder of record or beneficially in &#8220;street name&#8221; (through a broker, bank, or other nominee), stockholders may vote their shares without attending the Annual Meeting, by granting a proxy, or, for shares held in street name, by submitting voting instructions to your broker or nominee. Instructions for voting shares through each of the foregoing methods are included in the Company&#8217;s proxy materials and are summarized below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Board of Directors and management of Diffusion Pharmaceuticals Inc. appreciate the support and thanks its stockholders for their investment in Diffusion Pharmaceuticals.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>2021 Annual Meeting of Stockholders</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The 2021 Annual Meeting of Stockholders of Diffusion Pharmaceuticals, Inc. will be held Friday, June 25, 2021, at 1:00 p.m., ET, virtually via the internet at <u>www.meetingcenter.io/204775050</u>; the password for the meeting is DFFN2021<b>.</b> <b>To access the virtual meeting, stockholders must have the information printed in the proxy materials.</b> To vote your shares, stockholders must go online or request a paper copy of the proxy materials to receive a proxy card. Further information can be found in the proxy materials filed with the SEC on April 30, 2021, which can be accessed via <u>https://investors.diffusionpharma.com/sec-filings/sec-filings</u>.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="img01.jpg" src="img01.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stockholders may also submit questions prior to the date of the Annual Meeting by e-mailing them to&nbsp;<u>proxyrequests@diffusionpharma.com</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>If I was a Diffusion stockholder as of the record date, how do I vote my shares?</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>If you are a registered stockholder</b> (i.e., you hold your shares through our transfer agent, Computershare), you do not need to register to attend the Annual Meeting virtually. As the stockholder whose shares are registered in your name, you may vote your shares by one of the following methods:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:1.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Virtually,</b>&nbsp;by joining the Annual Meeting and following the voting instructions available</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">on the meeting portal during the meeting.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:1.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Vote by Internet,</b>&nbsp;by going to the web address <u>http://www.envisionreports.com/DFFN</u></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">and following the instructions for Internet voting shown on your proxy card.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:1.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Vote by Telephone,</b><b><i>&nbsp;</i></b>by dialing 1-800-652-8683 and following the instructions for</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;telephone voting shown on your proxy card<b><i>.</i></b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>If you hold your shares through an intermediary, such as a bank or broker, you must register in advance using the instructions below</b>.</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To register to attend the Annual Meeting online by webcast you must submit proof of your proxy power (legal proxy) reflecting your holdings along with your name and email address to Computershare. Requests for registration must be labeled as &#8220;Legal Proxy&#8221;&nbsp;and be received no later than 5:00 p.m., Eastern Time, on June 22, 2021.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">You will receive a confirmation of your registration by e-mail after Computershare receives your registration materials.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Requests for registration should be directed to Computer through the following means:</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By email : Forward the email from your broker, or attach an image of your legal proxy, to <u>legalproxy@computershare.com</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About Diffusion Pharmaceuticals Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body&#8217;s ability to deliver oxygen to areas where it is needed most. Diffusion&#8217;s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#8217;s most intractable and difficult-to-treat conditions. In addition to TSC, Diffusion&#8217;s product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development. For more information, please visit us at <u>www.diffusionpharma.com</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="img01.jpg" src="img01.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company&#8217;s upcoming annual meeting of stockholders. The Company may, in some cases, use terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately,&#8221; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company&#8217;s control, and as a result the Company&#8217;s actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risk and uncertainties include, among other things, those related to: the Company&#8217;s ability to obtain a quorum of holders sufficient to properly convene its annual meeting of stockholders under its bylaws; general economic, political, business, industry, and market conditions, including the ongoing COVID-19 pandemic; and the other factors discussed under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s filings most recent Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified) and, except as required by applicable law, rule, or regulation, the Company undertakes no obligation to update any such statements after the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Contacts</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investors:</b>&nbsp;&nbsp;<br>
<u>Tiberend Strategic Advisors, Inc.&nbsp;</u><br>
Maureen McEnroe, CFA/Lisa Sher<br>
<u>mmcenroe@tiberend.com</u>&nbsp;/&nbsp;<u>lsher@tiberend.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Media:</b>&nbsp;&nbsp;<br>
Kate Barrette<br>
RooneyPartners&nbsp;&nbsp;<br>
(212) 223-0561<br>
<u>Kbarrette@rooneyco.com</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>d01.jpg
<TEXT>
begin 644 d01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M<O@[SG&&MYD923ZY!!_"O(]#F:VU_3I8V.];B,!C[R 'MQGGCIG/KSWGQ/\
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M=2>WAV1[55 !@>_US7HK3)'&TDDB*B]6)P!VY/UKQOX #/@_Q43QNU6?H/\
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+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img01.jpg
<TEXT>
begin 644 img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MO_0S7I.@_P#)N*_]@"7_ -%-0!XG\$/#VE>)?'D]EKME'>6RV,D@C<D ,'0
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M7W)H U?VAO\ DJ"_]>,7\VKUCQ5J<MC\(]#MX&*F\M;>-R/[HB!(_' KR?\
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MGK0!+J7A;0-8NOM.K:+87L^T+YMQ;J[8'09(Z<UIPQ1V\*0P(L<4:A411@*
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M!>V^X-Y5Q&'7(Z'!JW16IYY1TO1-+T2%XM'TZUL8Y&W.EM$L88],D 5>HHH
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; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
